Regulators Push for Evidence-Based Drug Approval, Streamlining Biosimilar Trials
What happened
The U.S. Food and Drug Administration and the European Medicines Agency are being urged to adopt evidence-based principles for drug regulation. This includes eliminating redundant biosimilar trials when rigorous scientific evidence already confirms similarity between medicines. The FDA previously announced draft recommendations aimed at streamlining certain pharmacokinetic testing requirements.
From newsweek.com
Why it matters
Eliminating unnecessary studies could reduce the costs associated with drug development and delay competition, potentially making life-saving medicines more accessible. Biosimilars, which are highly similar to approved biologic medicines, offer potential for more affordable treatment options.
Both the FDA and the European Medicines Agency govern drug approval processes.
From newsweek.com
Who's involved
- FDAU.S. regulatory agency that announced draft recommendations to streamline testing requirements.
- European Medicines AgencyHighest regulatory authority in the European Union that coordinates with the FDA on standards.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- AbbVieSpeculative
AbbVie might see reduced R&D costs and time for biologics and biosimilars due to regulatory streamlining.
- BioconSpeculative
Biocon could benefit from lowered barriers to entry and reduced costs for biosimilar manufacturing.
- WuXi BiologicsSpeculative
WuXi Biologics could see increased demand for its services as drug development becomes cheaper.
Keep exploring
The entities involved
- FDA
-
European Medicines Agency
highest regulatory authority on medicines in the European Union
Related events
- The Charlotte Lozier Institute found that the FDA lacked sufficient evidence in its review process.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- MDR/IVDR reforms require adoption by the European Parliament, referencing US FDA pre-submission meetings.
- Unregulated products are bypassing official government approval processes.